These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17601317)

  • 1. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term prevention of MS: effectiveness alone is not enough].
    Haas J
    Krankenpfl J; 2005; 43(7-10):237. PubMed ID: 16515307
    [No Abstract]   [Full Text] [Related]  

  • 3. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
    Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
    Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 7. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple sclerosis].
    Itoyama Y
    No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 14. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 15. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 17. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 19. Betaseron: a breakthrough treatment for multiple sclerosis.
    Morrison W; Nelson J
    Can Nurse; 1996 Oct; 92(9):38-41. PubMed ID: 9118060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.